Edition:
India

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

9.46USD
14 Dec 2018
Change (% chg)

$-0.03 (-0.32%)
Prev Close
$9.49
Open
$9.43
Day's High
$9.55
Day's Low
$9.26
Volume
36,899
Avg. Vol
136,611
52-wk High
$16.70
52-wk Low
$6.20

Latest Key Developments (Source: Significant Developments)

Aldeyra Therapeutics Says Repaid All Outstanding Indebtedness
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS - ON NOV 20, CO REPAID IN FULL ALL OUTSTANDING INDEBTEDNESS & TERMINATED ALL COMMITMENTS UNDER LOAN & SECURITY AGREEMENT.ALDEYRA THERAPEUTICS - DID NOT INCUR MATERIAL EARLY TERMINATION PENALTIES DUE TO REPAYMENT OF INDEBTEDNESS OR TERMINATION OF LOAN AGREEMENT.  Full Article

Aldeyra Therapeutics Inc Announces Public Offering Of Common Stock
Friday, 28 Sep 2018 

Sept 27 (Reuters) - :ALDEYRA THERAPEUTICS, INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.25 MILLION COMMON SHARES PRICED AT $13.75PER SHARE.  Full Article

Aldeyra Therapeutics Announces Positive Results From Phase 2B Dry Eye Disease Clinical Trial
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 2B DRY EYE DISEASE CLINICAL TRIAL.ALDEYRA THERAPEUTICS INC - PIVOTAL CLINICAL TESTING EXPECTED TO BEGIN IN 2019 FOLLOWING DISCUSSION WITH REGULATORY AUTHORITIES.ALDEYRA THERAPEUTICS INC - STATISTICALLY SIGNIFICANT IMPROVEMENT ACROSS MULTIPLE SYMPTOM AND SIGN MEASURES.ALDEYRA THERAPEUTICS INC - EARLY ONSET AND BROAD RANGE OF ACTIVITY SUPPORTS DIFFERENTIATED PRODUCT PROFILE.ALDEYRA - CONSISTENT WITH PREVIOUS CLINICAL TRIALS, TOPICAL OCULAR REPROXALAP WAS WELL TOLERATED, AND REPORTED ADVERSE EVENTS WERE GENERALLY MILD.  Full Article

Aldeyra Therapeutics Appoints Joshua Reed As CFO
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS APPOINTS JOSHUA REED AS CHIEF FINANCIAL OFFICER.ALDEYRA THERAPEUTICS INC - APPOINTMENT OF JOSHUA REED AS CHIEF FINANCIAL OFFICER.ALDEYRA THERAPEUTICS INC - REED WILL SUCCEED STEPHEN TULIPANO, COMPANY'S OUTGOING CHIEF FINANCIAL OFFICER.  Full Article

Aldeyra Therapeutics Announces Q1 Loss Per Share $0.43
Tuesday, 15 May 2018 

May 15 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.43.Q1 EARNINGS PER SHARE VIEW $-0.39 -- THOMSON REUTERS I/B/E/S.QTRLY BASIC AND DILUTED NET LOSS PER SHARE $0.43.  Full Article

Aldeyra Therapeutics Announces Year End 2017 Financial Results
Thursday, 29 Mar 2018 

March 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES YEAR END 2017 FINANCIAL RESULTS.ALDEYRA THERAPEUTICS INC - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $42.9 MILLION AS OF DECEMBER 31, 2017.  Full Article

Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING.  Full Article

Aldeyra Therapeutics reports Q3 loss per share of $0.32
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.32.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.‍Cash, cash equivalents, and marketable securities were $47.9 million as of September 30, 2017​.  Full Article

Aldeyra ‍announcesd new data for ADX-102 from Phase 2 clinical trials
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra - ‍announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis​.Aldeyra Therapeutics Inc - ‍Aldeyra plans to commence phase 2B clinical testing of ADX-102 in dry eye disease in first half of 2018​.Aldeyra Therapeutics Inc - ‍ADX-102 generated clinically important responses statistically superior to vehicle in patients with allergic conjunctivitis​.Aldeyra Therapeutics Inc - ‍plans to commence Phase 3 clinical testing of ADX-102 in allergic conjunctivitis in first half of 2018​.  Full Article

ALDEYRA THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK
Tuesday, 14 Feb 2017 

Aldeyra Therapeutics Inc : ALDEYRA THERAPEUTICS INC PRICES PUBLIC OFFERING OF COMMON STOCK .SAYS PUBLIC OFFERING OF 2.22 MILLION COMMON SHARES PRICED AT $4.50 PER SHARE.  Full Article